Mankind Pharma Ltd

Mankind Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Mankind Pharma Ltd

₹ 2,479 -1.38%
22 May - close price
mankindpharma.com BSE: 543904 NSE: MANKIND
About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Key Points

Leadership[1]
- #1 Rank in Prescriptions over the last 8 yrs.
- #2 Rank by volume & #4 Rank by value in IPM
- 4 Consumer healthcare brands ranked #1 in their categories.

Website BSE NSE
  • Market Cap ₹ 1,02,342 Cr.
  • Current Price ₹ 2,479
  • High / Low ₹ 2,727 / 1,910
  • Stock P/E 50.9
  • Book Value ₹ 395
  • Dividend Yield 0.04 %
  • ROCE 13.5 %
  • ROE 13.1 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Promoter holding has decreased over last 3 years: -3.84%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
2,053 2,579 2,708 2,607 2,422 2,868 3,061 3,199 3,079 3,570 3,697 3,567 3,443
1,636 1,924 2,025 2,000 1,836 2,196 2,214 2,383 2,396 2,724 2,776 2,648 2,513
Operating Profit 417 655 683 606 586 672 847 816 683 847 921 919 930
OPM % 20% 25% 25% 23% 24% 23% 28% 26% 22% 24% 25% 26% 27%
50 63 63 75 94 108 109 87 249 83 94 -31 94
Interest 5 6 9 9 9 11 7 221 191 171 170 157 142
Depreciation 85 87 96 110 100 103 100 187 231 219 222 223 223
Profit before tax 377 624 641 562 572 666 849 495 511 540 624 509 659
Tax % 22% 21% 20% 18% 17% 18% 22% 22% 17% 18% 17% 19% 15%
294 494 511 460 477 543 659 385 425 445 520 414 559
EPS in Rs 7.13 12.15 12.51 11.33 11.76 13.39 16.31 9.22 10.20 10.62 12.39 9.90 13.43
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
3,334 5,865 6,214 7,782 8,749 10,260 12,207 14,278
2,748 4,427 4,565 5,791 6,848 7,743 9,182 10,660
Operating Profit 586 1,438 1,649 1,991 1,902 2,517 3,026 3,617
OPM % 18% 25% 27% 26% 22% 25% 25% 25%
76 122 183 210 141 295 548 241
Interest 2 23 21 60 46 34 432 639
Depreciation 39 99 119 167 326 378 621 886
Profit before tax 621 1,438 1,692 1,975 1,671 2,399 2,521 2,333
Tax % 29% 27% 24% 26% 22% 19% 20% 17%
445 1,056 1,293 1,453 1,310 1,942 2,011 1,938
EPS in Rs 219.33 25.72 31.59 35.78 32.00 47.75 48.26 46.34
Dividend Payout % 0% 0% 24% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 18%
3 Years: 18%
TTM: 17%
Compounded Profit Growth
10 Years: %
5 Years: 11%
3 Years: 17%
TTM: 16%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 23%
1 Year: 2%
Return on Equity
10 Years: %
5 Years: 17%
3 Years: 16%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 20 40 40 40 40 40 41 41
Reserves 2,035 3,445 4,682 6,115 7,395 9,323 14,291 16,259
0 131 241 873 170 207 8,511 6,312
968 1,449 1,397 2,080 2,080 2,313 4,808 5,468
Total Liabilities 3,022 5,065 6,360 9,108 9,686 11,883 27,652 28,080
316 1,600 1,664 3,588 4,251 4,545 19,005 19,093
CWIP 47 317 372 701 550 282 826 655
Investments 959 829 1,512 1,109 1,346 2,568 2,042 1,985
1,700 2,319 2,811 3,709 3,538 4,488 5,780 6,346
Total Assets 3,022 5,065 6,360 9,108 9,686 11,883 27,652 28,080

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,070 1,137 920 1,813 2,152 2,413 3,121
-436 -1,222 -1,369 -1,052 -2,081 -12,624 -196
-531 -8 605 -740 5 10,233 -2,953
Net Cash Flow 103 -92 156 22 77 22 -28
Free Cash Flow 853 826 -1,423 987 1,771 1,895 2,387
CFO/OP 97% 96% 71% 112% 103% 98% 103%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 22 33 19 18 24 30 46 44
Inventory Days 166 175 243 265 188 180 219 193
Days Payable 71 145 137 162 126 90 119 121
Cash Conversion Cycle 117 63 125 121 86 120 146 117
Working Capital Days 56 30 32 24 39 53 -28 -1
ROCE % 37% 32% 22% 26% 16% 14%

Insights

In beta
Mar 2012 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Market Share by Value in IPM
%

Log in to view insights

Please log in to see hidden values.

Login
Volume Rank in IPM
Rank
Chronic Share in Total Portfolio (Ex-BSV)
%
Doctor Coverage
Number (Lakh)
Field Force Strength
Number
Mankind PCPM (Per Candidate Per Month)
INR Lakhs
Prescription Share
%
Number of Stockists
Number
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
76.50% 76.50% 76.50% 74.88% 74.87% 74.87% 72.71% 72.70% 72.67% 72.67% 72.66% 72.66%
4.18% 4.18% 6.74% 9.87% 11.58% 12.37% 13.34% 12.92% 13.07% 12.83% 11.34% 10.24%
4.65% 4.56% 9.78% 11.14% 9.94% 9.91% 11.05% 11.47% 11.50% 11.91% 13.26% 14.46%
14.67% 14.76% 6.97% 4.10% 3.61% 2.86% 2.89% 2.89% 2.75% 2.57% 2.75% 2.63%
No. of Shareholders 1,31,9181,34,7311,27,4491,35,1161,53,4501,63,8541,71,2811,80,5971,79,5491,70,3471,77,5391,77,606

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls